This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Thursday's Health Winners & Losers

Health stocks amassed greater losses Thursday amid disappointing profit reports from several companies.

The Nasdaq biotechnology index, with 165 stock components, fell 11.6, or 1.5%, to 776.52 on Thursday. The index has been facing a swoon in the past week, down 4.7% since last Thursday's open.

Among individual stocks Thursday, earnings were in focus. 3SBio (SSRX) shares plummeted after the biotech company's fourth-quarter earnings and 2008 revenue forecast missed estimates. The company after the close Wednesday reported quarterly earnings of $2.4 million, or 11 cents per American depository share, shy of analysts' average target of 13 cents per ADS.

3SBio said it expects revenue in 2008 to range from $30 million to $32 million, while analysts had forecast a top line of $36.3 million. Shares tumbled $3.31, or 28.3%, to $8.39 on Thursday.

Quest Diagnostics (DGX) fell 5% after the testing company gave 2008 guidance below the Street view. The company said it expects to earn between $3 and $3.20 a share, while analysts forecast a profit of $3.36 a share.

For its last quarter, Quest reported a loss of $5.3 million, or 3 cents a share, reversing a year-earlier profit of $149.3 million, or 76 cents a share, in the year-ago quarter. When charges are factored out, the company's earnings of 79 cents a share beat analysts' estimates by a penny. Shares slipped $3.81, or 7.3%, to $48.35.

Also on the downside was Ligand Pharmaceuticals (LGND), which fell 13% to a 52-week low after its profit report. The drug company reported fourth-quarter net income of $5.9 million, or 6 cents a share, down from $141.4 million, or $1.61 a share, in the year-ago quarter. Shares slid 50 cents, or 12.5%, to $3.51.

Elsewhere, Psychiatric Solutions (PSYS) shares tumbled after the behavioral-health services company beat earnings estimates by a penny, but fell shy on revenue. The company recorded a fourth-quarter profit of $23.2 million, or 42 cents a share, up from $17.6 million, or 33 cents a share, during the same period a year prior. Analysts expected a 41-cent-a-share profit. Psychiatric Solutions registered revenue of $403.4 million, while analysts were looking for $413.6 million.

For 2008, the company expects earnings $1.93 and $1.97 a share, above Wall Street's target of $1.88. For the first quarter, however, Psychiatric Solutions forecast earnings of 42 cents to 43 cents a share, a penny short of estimates. Its shares dropped $4.03, or 12.7%, at $27.65.

Heading the other direction, Icon (ICLR), which provides outsourced development services, to pharma, biotech and medical device companies, gained $7.02, or 11.2%, to $69.64, on a stronger-than-expected earnings report.

The company reported fourth-quarter net income of $15.9 million, or 53 cents a share, up from $11.4 million, or 39 cents a share, in the year-ago period. Revenue climbed 40% to $180.7 million. The results beat Thomson Financial's average analyst estimate for earnings of 50 cents a share and revenue of $172.5 million.

CryoLife (CRY) also gained after posting earnings that topped estimates. The company said fourth-quarter earnings rose to $2.6 million, or 10 cents a share, from $50,000, or a penny a share, a year earlier. Revenue rose 19% to $25.1 million. Analysts forecast earnings of 6 cents a share on revenue of $24.1 million. CryoLife's stock surged $1.06, or 11.8%, to $10.03.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs